Bermekimab

Bermekimab^[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A).^[2] As of March 2017^[update], bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer^[3] and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.^[4]

Bermekimab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL1A
Clinical data
Trade names	Xilonix
Other names	MABp1
Routes of administration	intravenous
ATC code	L01FX11 (WHO)
Identifiers
CAS Number	1401965-15-8
DrugBank	DB14947
ChemSpider	none
UNII	N6SVN735GY
KEGG	D11253
Chemical and physical data
Formula	C6464H10024N1736O2000S44
Molar mass	145468.09 g·mol−1

Bermekimab is being developed by XBiotech Inc.^[5]